P eople with serious and complex medical illnesses account disproportionately for health care utilization, but this expenditure yields poor value.
1,2 A quarter of Medicare beneficiaries die in acute care hospitals, and many experience intensive care unit admission and health care transitions in the last weeks of life, indicating high-intensity care inconsistent with patient preferences. 3 Costs are increasing because of not only increasing prevalence of serious chronic disease [4] [5] [6] but also increasing unit costs of medical care, including hospital care. 7, 8 Reforming a system originally designed to provide acute, episodic care is essential for its longterm sustainability. [9] [10] [11] Palliative care is an interdisciplinary specialty focused on improving quality of life for seriously ill patients and their families through symptom management, communication, and patient autonomy. 12, 13 A review of the literature to July 31, 2013, found that palliative care consultation (PCC) teams are associated with reduced hospital costs but that heterogeneity of methods precluded meta-analysis. 14, 15 Reported methods may also have biased treatment effect estimates and disguised important associations. 15, 16 Previous studies have found that estimating the association of PCC with hospital costs requires incorporating time from admission to consultation 16, 17 and consideration of patient characteristics that may influence the magnitude of the estimate, including primary diagnosis and number of comorbidities. 18, 19 Few PCC programs meet national staffing guidelines in the United States, 20, 21 and there is a need worldwide for improved evidence on this intervention. 22 Such evidence could inform allocation of existing palliative care capacity, efforts to address staff shortages, and future evaluations of care to populations with serious and complex medical illness.
The aims of this analysis were to estimate the association of PCC with total direct cost of hospital care for adults with serious illness and to examine whether this estimated association varies by primary diagnosis and number of comorbidities. Prior reviews found that meta-analysis of published estimates is not possible because of heterogeneity 14, 23 and limitations in methods. 15, 16 Therefore, the aim was pursued through 5 sequential objectives: (1) literature search to identify all economic evaluations of PCC for adult hospital inpatients to August 31, 2017; (2) study selection to appraise all evaluations and identify those that were suitable for methods that incorporate intervention timing, 16, 17 controlling appropriately for confounding, 15 and stratification by clinical factors 18, 19 ; (3) data access to approach each suitable study's lead author and invite collaboration through data sharing; (4) estimation of the association of PCC with total direct costs within each collaborating study data set and for subsamples defined by primary diagnoses and number of comorbidities at admission; and (5) meta-analysis to pool these estimates to address our primary aim.
We hypothesized that PCC is estimated to reduce hospital costs, consistent with prior studies 14, 24 that have identified lower intensity of hospital treatment and shorter length of stay for patients receiving PCC. We hypothesized that this estimated association would be greater for patients with primary diagnosis of cancer than those with a primary noncancer diagnosis because inpatients with cancer are typically receiving more aggressive care that palliative care may be more able to influence. 9 In addition, we hypothesized that the estimated association would be greater for patients with more comorbidities on the basis that palliative care's interdisciplinary approach may have a greater change in treatments for patients with complex needs (eg, polypharmacy) than for those for whom single disease-focused treatment remains appropriate. 19 
Methods
All studies included in this meta-analysis received relevant institutional review board approval from their sites at the time of the original study. Appropriate data-sharing protocols have been followed in reanalyzing the data for this study: where permitted, principal investigators (PIs) made available anonymized patient-level data to one of us (P.M.); where data were not permitted to be shared, the PI conducted analyses under the direction of one of us (P.M.).
resolved in discussion between reviewers and another coauthor (R.S.M.). Only English-language peer-reviewed journal articles were considered. One author (R.S.M.) contacted investigators known to be active in this field to ask whether other data sets, including unpublished data sets, existed and were available for analysis. Articles were reviewed using Covidence software. 25 Data analysis was performed from January 3, 2017, to January 2, 2018. Details are available in the eMethods in the Supplement.
Study Selection
All economic evaluations identified were appraised by 2 independent reviewers (P.M. and C.N.) for suitability for reanalysis to our methods incorporating PCC timing and matching treatment groups on a minimum set of confounders. We emphasized data that would allow reliable and useful treatment effect estimation: a sample of inpatients with serious illness, baseline data on important confounders and details on PCC provision, and direct costs as an outcome of interest (direct costs are the most reliable indicator of short-term hospital resource 26 ). The authors followed PRISMA in study selection. Details are available in the eMethods in the Supplement.
Data Access
For each suitable study, we invited collaboration. In the first instance, we approached the corresponding author using contact details published with their article and sought approval from the PI. When this approach did not yield contact, we pursued other avenues to contact the corresponding author (eg, searching online) and by approaching coauthors. All studies for which PIs agreed to collaborate were included in the metaanalysis; all studies for which the PIs refused or were unable to participate or did not acknowledge our inquiries were excluded.
Patient Eligibility Criteria
For each study, we retained individuals only if they were recorded as having at least 1 of 7 conditions: cancer; heart, liver, or kidney failure; chronic obstructive pulmonary disease; AIDS/ HIV; or selected neurodegenerative conditions. Patients who were admitted for trauma or received an organ transplant were excluded. All diagnoses, trauma, and transplants were identified using hospital International Classification of Diseases, Ninth Revision (ICD-9) codes (eMethods in the Supplement). The number of comorbidities was calculated according to the Elixhauser index 27 using ICD-9 codes.
Subsamples
For analyses stratifying by primary diagnosis, within each study, we separated all those with a primary diagnosis of cancer and noncancer. Therefore, noncancer groups included a small number of patients with a secondary diagnosis of cancer because primary diagnosis was the principal reason for admission. For analyses that stratified samples by comorbidity, we anticipated that the mean and distribution of comorbidity counts would vary among the studies. Therefore, we waited until all data for analysis had been obtained with the intention to compare comorbidity distributions across samples and use the largest number of strata that could support balance of treatment and comparison groups. Details are available in the eMethods in the Supplement.
Dependent and Independent Variables
Our dependent variable was total direct cost of hospital stay. Direct costs are taken from the accounting database of each hospital site and are traceable to specific staffing, equipment, pharmaceuticals, and procedures during an inpatient stay. 26 Our primary independent variable was a binary exposure variable: did the individuals receive a PCC within 3 days of admission? Incorporating intervention timing in economic evaluation of PCC increases the accuracy and usefulness of treatment effect estimates and reduces the risk of a false-negative result. [15] [16] [17] There are different possible approaches to controlling for timing. 16 For this meta-analysis, we examined the distributions of consultation timing in all included data sets and selected within 3 days of admission as the specification that best balances competing considerations in defining the exposure variable by timing in observational studies. Details are available in the eMethods in the Supplement.
Additional independent variables were all factors collected at admission that we hypothesized could be associated with treatment and outcome. Uncontrolled-for proximity to death is a particular concern in observational studies of end-of-life populations, but controlling explicitly for mortality raises endogeneity concerns because this is associated with our exposure variable (individuals with higher proximity to death are more likely to receive palliative care) and our outcome of interest (proximity to death is associated with increasing costs). 15 We used ICD codes to generate 2 comorbidity measures: the Elixhauser index, 27 an additive count of the presence of 31 serious conditions to act as a measure of illness burden, and the van Walraven index, 28 a weighted count designed specifically to predict in-hospital mortality. In addition, we performed sensitivity analysis with hospital decedents removed (eMethods in the Supplement).
Bias
In a meta-analysis 29 of seriously ill populations, observational designs dominate, treatment and comparison groups often differ on observed factors (eg, higher illness burden among palliative care populations), and there may also be a risk of bias through unobserved differences (eg, physician attitude to palliative care). Two main strategies are available in trying to minimize bias: instrumental variables 30 and propensity scores. 31, 32 Instrumental variables allow for control of unobserved confounding, whereas propensity scores control only for observed baseline confounders. 33 However, a valid instrument is often hard to identify, especially in routinely collected data, and propensity scores are the most widely used approach to managing confounding. 14, 15 To control for confounding in observational studies, we used an instrumental variable if available. 34 When no instrument was available, we balanced treatment groups in each study on all baseline variables using the covariate balancing propensity score method. 31, 33, 35 We created inverse probability of treatment weights from the estimated propensity score for analyses. Before estimating treatment effects, we evaluated the balance between treatment groups for the overall sample, performing balance diagnostics and taking a 10% mean standardized difference between the treatment group and comparison group to constitute sufficient support. 36 We also checked balance across the distribution of the propensity score. 37 
Statistical Analysis
For each estimate, we regressed total direct costs on our treatment variable and other independent predictors in a weighted sample using generalized linear models with a γ distribution and a log link selected following model evaluation. 38, 39 We estimated the average treatment effect on the treated (ATET), the typical treatment effect in those who received PCC, holding all other values constant. All regressions were calculated with bootstrapped SEs (1000 replications). 40 Where the sample or treatment group was redefined, new propensity scores were calculated. 41 No patient in our final analytic sample had missing data in the dependent or independent variables or in receipt and timing of palliative care. Propensity scores were calculated in R, 35 and regressions estimating treatment effects were performed with Stata software, version 12 (StataCorp). 42 For all tests, P < .05 was deemed to be statistically significant. Regression output (sample sizes, mean estimated ATETs, and associated 95% CIs) were combined in the meta-analysis to calculate pooled ATETs and CIs. Differences between ATETs for cancer and noncancer samples were assessed using unpaired t tests. Differences between ATETs for samples defined by the number of comorbidities were assessed using 1-way analysis of variance (ANOVA) and posthoc Tukey honest significant difference tests when the ANOVA test statistic was significant at P < .05.
Results
The literature review identified 17 economic evaluations of PCC. Of these 17, we assessed 8 as suitable for the meta-analysis, and these PIs were invited to collaborate. 17, 18, [43] [44] [45] [46] [47] [48] Of these 8, 6 accepted the invitation. 17, 18, [43] [44] [45] 48 One PI was unable to participate because the data were no longer available, 46 and one PI and their team did not respond to multiple attempts at communication. 47 Therefore, 6 samples were included in the study, with a total 133 118 patients (range, 1020-82 273), of whom 93.2% were discharged alive (range, 89.0%-98.4%), 40.8% had a primary diagnosis of cancer (range, 15.7%-100.0%), and 3.6% received a PCC (range, 2.2%-22.3%) (Figure) .
An overview of the 6 data sets is provided in Table 1 . The earliest study collected data from May 24, 2001 , to December 28, 2004 and the most recent from February 24, 2010, to October 1, 2015. All are from the United States, recording costs in US dollars, which we standardized to 2015, the final year of data collection, using the Consumer Price Index. 49 There was wide variation in the proportion of participants receiving PCC (3%-22%), proportion with a primary diagnosis of cancer (16%-100%), and sample size (1020-82 273). Mean Elixhauser indexes ranged from 2.2 to 3.5 among the studies. Data sources varied according to study design. Secondary cohort studies used routine administrative data, extracting baseline and outcome variables from the hospital databases. One primary cohort study complemented access to routinely collected data with original data collection from patient-reported measures and medical record review, and this therefore has the greatest number of baseline variables. In each study, hospitals recorded the presence of conditions using ICD-9 and receipt of PCC was recorded by dedicated databases operated by the palliative medicine service. One study 44 The estimated association of PCC within 3 days of admission with total direct costs for patients of all diagnoses and stratified by primary diagnosis of cancer or noncancer is presented in Table 2 . When patients were pooled irrespective of diagnosis, the meta-analysis estimate suggests a statistically significant reduction in costs (−$3237; 95% CI, −$3581 to −$2893; P < .001). In the stratified analyses, the pooled meta-analysis estimate suggests a statistically significant reduction for both the cancer (−$4251; 95% CI, −$4664 to −$3837; P < .001) and noncancer (−$2105; 95% CI, −$2698 to −$1511; P < .001) subsamples. For comparison of cancer and noncancer, the t test values were −1756 (P < .001) for the study by Morrison et al, 43 −8381 (P = .04) for the study by Penrod et al, 44 −5365 (P = .15) for the study by Morrison et al, 45 −6286 (P < .001) for the study by
McCarthy et al, 18 4373 (P = .02) for the study by May et al, 48 and −2146 (P < .001) for the pooled results. The meta-analysis treatment effect estimates for samples stratified by primary diagnosis and number of comorbidities (Elixhauser index) are given in Table 3 . For all patients irrespective of primary diagnosis, the magnitude of the estimated treatment effect was larger for subsamples with higher numbers of comorbidities. In posthoc analyses, the differences were significant for comparisons of the samples with 4 or more comorbidities with those with 2 or fewer comorbidities and in comparisons of those with 3 comorbidities and those with 1 or 0 comorbidities. The same results were found when equivalent analyses were run for participants with a primary diagnosis of cancer. Among patients without cancer, the magnitude of estimated treatment effect was greater for those with 4 or more comorbidities than for those with 2 or fewer.
Discussion
Our results suggest that PCC within 3 days of admission reduces direct costs for hospitalized adults with life-limiting illness and that there are important differences in the estimated treatment effect according to clinical factors. Treatment effect estimates were significantly larger for individuals with a cancer diagnosis than for those with a noncancer diagnosis and for individuals with 4 or more comorbidities compared with those with 2 or fewer. These results were derived using a single methodologic approach that addresses identified weaknesses in prior work, and they therefore reflect the state of the science of economic studies of PCC. Of importance, the correlation between estimated cost effect and the comorbidity total of the sample is the reverse of prior research that assumed that long-stay, high-cost hospitalized patients could not have their care trajectories affected by palliative care. 15 Current palliative care provision in the United States is characterized by widespread understaffing. 20 Our results suggest that acute care hospitals may be able to reduce costs for this population by increasing palliative care capacity to meet national guidelines. 21 Generalizability of results from the United States to other societies and health care systems is a b Instrumental variables are a statistical approach to controlling for unobserved confounding in observational studies. 30 An appropriate instrument is a factor that is correlated with the exposure variable conditional on all other baseline variables and is uncorrelated with the dependent variable (except through its effect on exposure). In the study by Penrod et al, 44 the instrumental variable was primary physician preference for palliative care; this process has been detailed elsewhere. h In 2 weeks before hospitalization.
i In morphine sulfate equivalents in the week before hospitalization. The van Walraven index was not used for the study be Penrod et al 44 because this study did not retain relevant International Classification of Diseases, Ninth Revision (ICD-9) data to calculate (but had already coded all patients for primary diagnosis and Elixhauser index using ICD-9 codes).
Economics of Palliative Care for Hospitalized Adults With Serious Illness
Original concern, and only by exploring similar questions in other settings can the international relevance of these results be fully understood. However, the general pattern of cost-saving observed in the United States is also reported in economic studies 50, 51 of hospital palliative care in other countries, and although some factors, such as access and incentives, may be specific to the United States, other challenges, such as appropriate decision making for individuals with complex illness in acute care settings, are universal. Further research is required to confirm these results with randomized clinical trials and prospective observational studies and to assess whether our hypothesized drivers of differences are accurate. Further examination of treatment effect heterogeneity offers the potential to reduce bias in these types of analyses and to identify populations for whom interventions such as PCC are more or less effective.
52 Future research must also expand beyond the hospital setting and perspective to estimate cost effects across settings and practitioners for all payers from initial consultation to death.
Strengths and Limitations
Our analyses represent a new standard in economic evaluation of the PCC intervention, and the identified weaknesses constitute a framework for further research. In addition to our methods that incorporate intervention timing and minimize observed confounding, a key strength of our study is the use of data from multiple sites, which increases confidence that our findings are generalizable to palliative care practice in different settings in the United States. All participating studies were identified through already published journal articles, which may be subject to publication bias, although detecting this is difficult because of the small number of studies. We inquired among authors in the field for relevant unpublished data, and none were identified. Eligibility criteria included articles in English, which may have excluded relevant material. For each included study, the PI approved data access and participated as an author on this meta-analysis, contributing to interpretation of the data. All studies used observational designs; thus, causation cannot be claimed, and 5 of 6 studies were retrospective studies that used routinely collected data only; our multimorbidity findings are consistent with a study 17 that was conducted prospectively and included original primary data collection. Our definition of the treatment as receiving palliative care within 3 days of admission was made using the available data rather than a priori, which would be optimal. However, no definitive guidelines defining the appropriate timing of palliative care exist. 53 We settled on our 3-day cutoff before estimating any treatment effects on the basis of maximizing sample sizes (and thus power) and minimizing risk of a type I error. Details on defining treatment by timing are available in the eMethods in the Supplement. Potential sources of unobserved confounding include preferences and treatment rationales; PCC is an intervention that may be provided to a broad range of clinical populations for a variety of reasons, 54, 55 and in all but one study 17 a few eligible individuals received palliative care, which may indicate that our criteria are insufficiently specific in defining palliative care need (and thus bias our results). However, the low numbers of palliative care receipt are consistent with data on widespread unmet need for patients with serious illness (and particularly persons with noncancer diagnoses), and our key conclusions hold in sensitivity analyses that control for discharge status. Our analyses were concerned only with costs within a single index hospital admission, which has important limitations for policy given that the optimal viewpoint in economic evaluation is the societal perspective, incorporating postdischarge use and out-of-pocket costs.
14,24 For example, cost savings observed in hospital settings may be passed to other parts of the health system or onto patients and their families, and we did not incorporate patient outcomes, meaning that lower costs are only beneficial on an assumption that outcomes for palliative care are at least as good as for usual care only (and magnitude of any association does not differ significantly among compared subsamples). 56,57 Total direct costs were heterogeneous because each institution uses different cost-accounting methods; however, cost pooling from different hospitals has been performed in multiple prior studies. 43, 45, 58 Stratified analyses may continue to disguise important effect differences. Specific cancer diagnoses and nonmalignant conditions will have different treatment options and prognoses, which may increase or decrease the scope of PCC to change patterns of care. Similarly, the multimorbidity analyses do not take account of specific additional conditions or combinations of conditions, which may have important implications for treatment options, including polypharmacy.
Distributions of ATETs may be sensitive to choice of modeling approach 59 ; however, we compared different model performance before regression analyses, and sensitivity analysis with standard regression did not substantively differ from our main results (eMethods in the Supplement). Finally, this metaanalysis did not weight according to study quality or year of publication, but changes in practice and attitudes to palliative care during the time frame of available data (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) suggest that more recent data may be more reflective of current practice.
Conclusions
Palliative care consultation within 3 days of hospital admission is estimated to reduce cost of care for hospitalized adults with life-limiting illness, and this reduction in cost was larger for patients with cancer than for those with a noncancer diagnosis and for those with 4 or more comorbidities than for those with 2 or fewer. These results suggest that palliative care is more effective in changing patterns of care for patients with higher illness burden and that it may be possible for acute care hospitals to reduce costs by expanding palliative care capacity. 
eMethods. Supplementary Methods

Selection of eligible patients
Subjects for this study were eligible if they had one of seven life-limiting conditions (cancer, heart failure, COPD, AIDS/HIV, selected neurodegenerative, renal failure, liver failure) and excluded if their primary diagnosis indicated trauma or if they received a transplant during their admission.
Conditions, traumas and transplant procedures were identified through ICD-9 codes from the hospital databases. Specific ranges of ICD-9 codes for these factors are provided in eTable 1. ii.
Study selection:
To appraise all evaluations, and identify those that are suitable for methods incorporating intervention timing, 3 5 controlling appropriately for confounding 4 and stratification by clinical factors; 6 7 iii. Data access: To approach the lead author of each suitable study and invite collaboration via data-sharing and new analyses;
Literature search
We searched CENTRAL, PubMed, EconLit, EMBASE, CINAHL and PsycINFO and databases using terms from relevant domains (e.g., palliative, hospice; economic*, cost*) to search titles, abstracts and subject fields. For details of our replicable search strategy in each specific database, see eTables 2-7. Step Subject heading or search term # of studies returned As shown in Figure 1 in the main manuscript, the six databases returned (372+665+17+1444+262+320=)3080 titles, the prior literature review included 10 titles added by hand and the approach to authors identified no additional studies of interest. The 3090 titles included 701 duplicates, leaving 2389 unique titles to review.
Two independent reviewers applied the same eligibility criteria as the prior review: (i) a credible economic evaluation of (ii) a specialist-led interdisciplinary palliative care consultation team for adult patients in (iii) the hospital inpatient setting, (iv) measuring the impact on costs, charges or other cost effectiveness measure and (v) assessing against a usual care (UC) comparator. Only Englishlanguage journal articles were considered.
Of 2389 unique titles, 2352 articles were rejected at title/abstract and 37 were reviewed at full text, of which 20 were excluded and 17 were classed as economic evaluations of PCC by our criteria. 
Stud selection
The 17 economic evaluations were appraised separately by two authors (PM and CN) for their suitability for re-analysis to a single methodological standard. The following additional criteria were onfounders: age, gender, insurance status, primary diagnosis, and comorbidities; (vii) the data recorded both whether each participant received or did not receive palliative care, and if so what day of the admission the first consult occurred; (viii) study eligibility criteria defined according to baseline factors only and not according to discharge status; (ix) one outcome of interest was total direct hospital costs for an inpatient episode of care. Direct costs were chosen as the best indicator of short-term resource use in a hospital setting -the outcome of interest that an intervention such as palliative care, in potentially changing treatment choices and discharge goals, can be hypothesized to effect. The alternatives to direct costs are total costs (direct plus indirect costs), which risk overestimating the magnitude of effects 26 ; daily costs, which give a distorted picture of resource use if treatment and comparison group differ in length of hospital stay 3 4 ; and charges, which are widely seen as ill-suited to economic evaluation. 27 28 The results of this appraisal are presented in eTable 9: eight studies are suitable and nine are excluded.
eTable 9. Economic evaluations (n=17) appraised for suitability for meta-analysis
Study
Is study suitable for re-analysis estimating PCC effect on hospital costs? Cowan, 2004 29 No. Fails to meet criterion (ix): only charges data reported. Penrod, 2006 Definition of treatment variable with respect to timing
Background
Recent methodological work has demonstrated that the magnitude of estimated effect for PCC on cost of hospital admission is systematically associated with the time from admission to first consultation. 3 The explanation for this phenomenon is clear and intuitive:
 Utilization data such as hospital costs are additive across the episode of care under study, so costs accrued from the point of admission are included in primary outcomes of interest total direct costs and daily direct costs (total direct costs/length of stay).
 Patients who receive a consultation later in the hospital stay therefore accrue more costs in proportional and absolute terms prior to receiving the intervention compared to patients who receive a consultation at admission (ceteris paribus). These costs are included in the outcome of interest but by definition cannot be affected by the treatment.
3
 Additionally, hospital costs do not accrue evenly over a hospitalization, being highest at the point of admission.
44
 Where patients can receive a first consult at any point in their admission, pooling all PCC patients into one treatment group and evaluating impact of PCC on hospital costs does not meaningfully specify the treatment and increases risk of a false negative (type I error) since the treatment group includes people who only received the intervention after accruing the overwhelming majority of their outcome of interest. 16 This determination raises concerns about early economic studies of PCC 4 and is a key motivating factor in conducting this meta-analysis.
While the evidence on timing and cost-effect is clear, appropriate ways to manage the issue with observational data remains an ongoing subject of research. Two approaches are visible in the literature:
approach offers the clearest definition of the intervention and therefore the most useful information. However, a problem is quickly apparent: once 0<t, it is not clear how to define the comparison group. If all usual care patients are included then this group will include patients whose length of stay (LOS)<t, and who therefore were never candidates for the intervention as defined. If instead usual care patients with t<=LOS are included then this is defining the sample by an outcome, raising endogeneity concerns. 4 II. D received first PCC within t T avoids the fundamental problem of (I), since all patients are admitted on day 0 and therefore all patients have the opportunity to receive a PCC within t irrespective of the value of t. Treatment and comparison groups can be defined according to clear rules. However, it has its own limitations. First, there are no clinical guidelines on which to base t. Setting t very narrowly, e.g. t<=1, arbitrarily excludes PC patients from the treatment group and reduces its sample size. But where t is increased so too increases heterogeneity of the interventions pooled and increases the risk of a type I error in evaluating the effect of timely PCC following admission. Second, it raises the question of how to handle late-consult PC patients those who receive their first PCC team interaction after t days in hospital. They can be excluded from the analysis or re-categorized as controls. The former approach risks losing information and sample size, the latter approach may bias results to the null if PCC reduces costs from the point it is administered, which some studies have suggested.
However, this can be managed through simple sensitivity analysis: confirming that key conclusions via one approach hold via the other. 5 
Defining our exposure group in this meta-analysis
Of the six studies included in our meta-analysis, three make some attempt at incorporating timing:
McCarthy (2015) uses Method I above, and May (2015 use Method II.
In this meta-analysis, we employ Method II for the reasons outlined above: treatment and comparison groups can be defined according to clear rules and sensitivity analyses can confirm if approach to late-consult PC patients is impacting results.
The decision nonetheless remains: what value to place on t?
Optimally this decision would be made a priori but there are no clinical guidelines to do so.
As summarized above, in a single study analysis, defining t raises two competing concerns in estimating robust results: the larger t is set, the risk of a type I error is increased; the smaller t is set, the smaller are the treatment groups which arbitrarily excludes PC patients from the treatment group, undermines the power of the calculations and may weaken the balance of the propensity score. In a meta-analysis such as this, an additional concern arises that distributions of first consult timing may differ between studies: if in Study A all PC patients received the intervention on day 0 and in Study B all did so on day 10 then pooling results for impact of PCC within 10 days of admission in A and B may be pooling effects for substantively different treatments.
In the absence of clinical guidelines and in light of these concerns, we examined the distributions of first consult timing in our data but prior to estimating treatment effect estimates. We ran models with direct costs as an outcome of interest and a fixed list of independent predictors ( Table 1 in the main manuscript) differentiated by how the treatment variable was defined (within 2|3|4|5|6 days of admission) and evaluated model performance on the Aikake Information Criterion (AIC) 45 and model fit. 46 Model performance did not substantively differ by timing. We therefore chose instead to set the value of t to manage sample size from those studies that were included in the data. We sought a minimum sample of 150 in each stratum, with a minimum of 10 in both treatment and comparison groups, also based on prior work 6 ). We found that t=3 is the smallest value (i.e.
minimizing risk of a type I error) while still preserving sufficient sample size to perform all of our intended primary analyses in all (sub-)samples. If t were set with a value lower than 3 then some comorbidity sub-sample analyses would not be possible in some datasets M A . Patients were therefore included in the treatment group if they received a consultation within three days of admission and otherwise included in the comparison group. This decision was made prior to estimating any treatment effect.
Conclusion
There is no foolproof approach to incorporating PCC timing into analyses of observational data but doing so is essential to the integrity of results. The absence of timing-sensitive methods in most economic studies of PCC was a critical motivating factor in undertaking the meta-analysis. Our methods in this paper reflect the best approach so far developed: define the intervention as PCC t prior to estimating treatment effects and perform sensitivity analyses to confirm robustness of key findings.
Multimorbidity analyses: stratification and evaluation
Background
In this meta-analysis we aimed to estimate the effect of PCC on direct hospital costs for sub-samples defined by comorbidity, following early studies that reported no impact of PCC for the sickest patients 4 and a more recent study that found a larger effect for those with greater illness burden. 6 All included studies recorded presence/absence of disease using ICD-9 codes and these were used to identify both primary diagnosis and comorbidities. We used the Elixhauser index to measure comorbidity counts; this is a widely used measure and has been shown to out-perform the most prominent alternative, the Charlson index, with routinely collected data.
47
Stratification A E x (where x is the highest number of comorbidities with sufficient sample size for all datasets to support estimation of PCC effect on direct costs. We aimed for a minimum sample of 150 in each stratum, also based on prior work 6 ). We hypothesized grouping those with 0 and 1 comorbidities together since in our experience, while it is possible to have one of the seven life-limiting conditions that are required for eligibility in our study and an Elixhauser total of 0, this is unusual. We did not set a value a priori for x, since the number of strata would vary according to sample size and Elixhauser distribution within each participating dataset (eTable 10). possible in both cancer and noncancer in one study. 35 By setting x at four, i.e. our comorbidity strata are 0/1 Comorbidities; 2 Comorbidities; 3 Comorbidities; 4+ Comorbidities, we are able to include all studies in eTable 10 (one sub-sample NONC/ET1 in 37 has nine PC patients and all others meet our a priori sought sample sizes). In examining the comorbidity strata for 36 we found poor balance (i.e.
consistently over 10% standardized difference on baseline confounders 48 ) between treatment and comparison groups due to low treatment group sample size and excluded this study from our comorbidity analyses. An alternative approach would have been to revise our original research questions and examine only two strata, e.g. 0-2 and 3+ comorbidities, for all six studies, but the team considered this unhelpfully narrowed the scope of those original questions. We prefer to examine four comorbidity strata in five studies than two strata in six studies.
Evaluation
Each regression output represents an ATET distribution which has a reported mean, bootstrapped standard error and sample size (all regressi '
This distribution can be reviewed graphically, e.g. eFigure 1. In comparing ATET estimates for two sub-samples, i.e. CANC and NONC for any given study in Table   2 of the main manuscript, we use standard independent two-sample t-tests with the regression output. In pooling ATET estimates for a given set of sub-samples, e.g. CANC for all six datasets in Table 2 of the main manuscript, we combine the six distributions using mean ATET, SE and PCn.
In comparing the ATETs for four comorbidity strata (within ALL, CANC or NONC sub-samples), we used one-way ANOVA tests. This is a more conservative approach than alternatives, e.g. six head-tohead t-tests and allows us to examine not only the general association between Elixhauser totals and estimated ATET (which may not be linear in any case), and instead examine specific comparisons in post-hoc tests, e.g. does PCC estimated effect differ between ET1 and ET2 (single disease and multimorbidity) or ET1 and ET4 (single disease and high complexity) or both.
All pooled results, t-tests of difference and ANOVA results can be derived using the 'egression output in this data supplement.
Summary
In the abstract, an optimal approach to examining treatment effect heterogeneity by comorbidity counts would have incorporated a priori setting of the comorbidity strata. However, there are no clinical guidelines on which comorbidity count cut-offs could be specified and we sought to maximize 0 .001
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-3000 -2800 -2600 -2400 -2200 ATET the use of our available data. We therefore examines comorbidity counts in our datasets prior to treatment effect estimation and set cut-offs as 0/1, 2, 3 and 4+ as the approaches that maximized number of strata within all participating studies through sample size management. We evaluated differences between ATET estimates across strata using ANOVA one-way tests, which is a conservative way of evaluating differences in means between groups given sample sizes and standard errors.
Regression outputs from our reported analyses (Tables 2 and 3 
in main manuscript)
In the main manuscript we detail our approach to treatment effect estimation for a given (sub)sample and study: in the weighted sample, we regress direct cost of hospital care on our primary independent variable (did the subject receive a PCC within three days of admission?) and a fixed list of predictors. We perform bootstrapping (1000 reps) in estimating the average treatment effect on the treated (ATET).
In this section of the appendix, we provide the regression output for all ATETs in our primary analyses. That is:
 For each study we present the ATET for all subjects irrespective of diagnosis, for samples stratified by primary diagnosis cancer/noncancer, and (excluding Penrod 2010) samples stratified by Elixhauser.
 Results for all diagnoses and stratified by cancer/noncancer correspond directly to those reported in Table 2 in the main manuscript.
 Results by Elixhauser comorbidity total were pooled and presented (one pooled ATET per comorbidity stratum) in Table 3 in the main manuscript.
Data (mean ATET, distribution, sample size) presented here are sufficient to derive all pooled estimates and perform all tests of difference we report in the main manuscript. Note that sample size in any such calculation is the PCn, since the estimates are for the treated. 
